GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals: Board Meeting to Consider Q2 and H1 FY27 Unaudited Results
RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 22 Oct 2026, 07:14 PM IST  ·  BSE ID: c6f14cb4-6081-4835-8ca2-84893ccfb620
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board will meet on November 3, 2026, to approve its financial results for the quarter and half-year ending September 30, 2026.
🤖 AI Summary
  • Shukra Pharmaceuticals' Board to meet on Tuesday, November 3, 2026, to consider financial results.
  • Agenda includes approval of unaudited financial results for Q2 FY27, period ending September 30, 2026.
  • The Board will also approve unaudited half-year financial results ended September 30, 2026.
  • Auditor's Limited Review Report for the said periods will be considered during the meeting.
  • Meeting convened pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this intimation of a Board Meeting.
👤
Who Is Affected
All shareholders are indirectly affected as the upcoming financial results will provide updated information on the company's performance, which may influence future decisions.
🔍
Management Signal
The scheduling of the Board Meeting indicates management's adherence to regulatory timelines for disclosing financial results.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Shukra Pharmaceuticals' Q2 and H1 FY27 unaudited financial results after November 3, 2026.
Any declarations or specific business decisions arising from the Board Meeting on November 3, 2026.
Review of the Auditor's Limited Review Report for Q2 and H1 FY27.
LOW RISK This filing is a routine intimation of a board meeting, presenting no immediate new risks.
💡 Investor Takeaway
Shukra Pharmaceuticals has scheduled a Board Meeting on November 3, 2026, to consider and approve unaudited financial results for the second quarter and half year ended September 30, 2026, along with the Auditor's Limited Review Report. No financial figures are available in this intimation.
📅 Company Track Record
Shukra Pharmaceuticals reported an FY26 Net Profit of Rs. 2,196.88 Lakhs and a Q4 FY26 Standalone Net Profit of Rs. (18.79) Lakhs. The company recommended a dividend of Rs. 0.01 per share for FY26. A preferential issue of ₹ 3,94,65,500 showed no deviation in fund utilization.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
When is Shukra Pharmaceuticals Ltd's next Board Meeting scheduled?
Shukra Pharmaceuticals Ltd's next Board Meeting is scheduled for Tuesday, November 3, 2026.
What is the primary agenda of Shukra Pharmaceuticals' Board Meeting on November 3, 2026?
The primary agenda is to consider and approve the unaudited financial results for the second quarter and half year ended September 30, 2026.
Will an Auditor's Report be presented at the upcoming Board Meeting?
Yes, the Auditor's Limited Review Report for the second quarter and half year ended September 30, 2026, will be considered at the meeting.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.